Stay updated on Effect of Oral AT1001 in Fabry Disease Clinical Trial
Sign up to get notified when there's something new on the Effect of Oral AT1001 in Fabry Disease Clinical Trial page.

Latest updates to the Effect of Oral AT1001 in Fabry Disease Clinical Trial page
- Check3 days agoChange DetectedThe footer revision label was updated from v3.6.5 to v3.6.6, representing a minor system update. No study content, results, or page functionality appear to be affected.SummaryDifference0.0%

- Check11 days agoChange DetectedA new line stating '2009 ( U.S. NIH Grant/Contract )' was added to the study details. It provides funding attribution for the trial.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5. This reflects a minor platform update that does not change the displayed study details or how users interact with the page.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, reflecting a minor update to the page. This is a metadata/version update and does not alter the study data or eligibility details shown on the page.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision: v3.6.3 replaces v3.6.0 on the page, indicating a backend update to the study page. This change primarily concerns the page’s versioning and metadata rather than the study content.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page now shows a recruitment status note indicating enrollment has ended for this Fabry disease study. It also adds new help and navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and includes a minor formatting/version update (Intervention/Treatment heading and Revision: v3.6.0).SummaryDifference0.4%

Stay in the know with updates to Effect of Oral AT1001 in Fabry Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Oral AT1001 in Fabry Disease Clinical Trial page.